Cannabis Global to Begin Production of Northern Lights Branded Cannabis Products at Lynwood, California Facility April 1st

Rhea-AI Summary

Cannabis Global, Inc. (OTC PINK:CBGL) has announced the start of production for its Northern Lights branded cannabis products at its newly acquired facility in Lynwood, California, beginning April 1st. The company holds a 56.4% controlling interest in Natural Plant Extract (NPE), which specializes in cannabis manufacturing and distribution. The facility is equipped with a Type 7 license, allowing for versatile cannabinoid extraction, and features tax advantages that enhance profit margins. Cannabis Global plans to leverage this operation for product development and research on innovative cannabis technologies.

Positive

• Production of Northern Lights cannabis products starts April 1st.
• Acquisition of 56.4% controlling interest in NPE enhances business capabilities.
• Type 7 license allows for versatile extraction methods, boosting product range.
• Low local tax rates (1.5% distribution and 2% manufacturing) increase competitiveness.

Negative

• None.

LOS ANGELES, CA / ACCESSWIRE / March 31, 2021 / Cannabis Global, Inc. (OTC PINK:CBGL), an innovation-oriented company involved in disruptive areas of the cannabis and hemp-related industries, today announces the commencement of production of Northern Lights branded cannabis products beginning April 1st. The Company recently acquired a controlling interest in Natural Plant Extract (NPE), a licensed cannabis manufacturing and distribution operation in Lynwood, California, a suburb of Los Angeles. Manufacturing at the facility will include several new lines of cannabis edibles and cannabis flower-based products.

Arman Tabatabaei, CEO of Cannabis Global commented, "Several of the products we will be producing at NPE are based on unique technologies, including our inventions previously utilized for our hemp-based products. We also plan to utilize the new facility as a testbed to continue research and development efforts relative to our polymeric nanotechnologies, which are designed utilizing only natural ingredients. We feel strongly cannabis-related consumer markets will continue to demand cleaner labels, which we feel our unique and patent-pending technologies will be able to provide."

Cannabis Global believes the Lynwood facility is optimal for cannabis manufacturing and distribution. The site is approved for all types of cannabis manufacturing, included in the Type 7 license, which permits all types of solvents (including volatile) to extract cannabinoids from cannabis plant material. Local jurisdictions and the state of California severely restrict the issuance of type 7 licenses making ownership highly prized. Additionally, Lynwood offers one of the lowest city tax rates in the state of California with a 1.5% distribution tax and 2% manufacturing tax, making NPE more competitive than almost any other company in California with stronger margins.

In February, Cannabis Global increased its ownership stake to a 56.4% controlling interest in Natural Plant Extract. In addition to business opportunities available from product manufacturing and distribution to all parts of California, Cannabis Global also sees strong synergies between the NPE operations and its developing technologies in the areas of secure cannabis transport cannabis and cannabis infusions for both edible and flower-based products. Thus far, the Company has filed six provisional patents, three non-provisional patents and has recently announced its Comply Bag™ secure cannabis transport system with integrated track and trace capabilities via smartphones which will be available soon.

About Cannabis Global, Inc.

Cannabis Global, Inc. is a Los Angeles based, fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading under the stock symbol CBGL. We are an emerging force in the cannabis marketplace with a growing product and proprietary intellectual property portfolio. We are marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport, and tracking. We are also the developer and marketer of the Hemp You Can Feel™ brand, and the corporation is a major shareholder in Natural Plant Extract, a Southern California licensed cannabis manufacturer and distributor, which licenses our technologies to produce edibles for the cannabis marketplace. Cannabis Global has filed three non-provisional and multiple provisional patents for cannabis infusion and nanoparticle technologies and continues an active research & development program.

Cannabis Remains an Illegal Schedule 1 Drug Under Federal Law

Thirty-five states, including Colorado, the District of Columbia and four U.S. Territories currently have laws broadly legalizing cannabis in some form for either medicinal and/or recreational use governed by state specific laws and regulations. Although legalized in some states, cannabis is a "Schedule 1" drug under the Controlled Substances Act (21 U.S.C. § 811) ("CSA") and is illegal under federal law. Cannabis and its derivatives are viewed as being highly addictive and having no medical value. The United States Drug Enforcement Agency enforces the Controlled Substances Act, and persons violating it are subject to federal criminal prosecution.

As a result of the November, 2020 federal elections, and the election of Joseph R. Biden as president, it is expected that the federal government will move to amend parts of the CSA and de-schedule cannabis as a Schedule 1 drug.

In late January, 2021, Senate Majority Leader Chuck Schumer said lawmakers are in the process of merging various cannabis bills, including his own legalization legislation. He is working to enact reform in this Congressional session. This would include the Marijuana Freedom and Opportunity Act, that would federally de-schedule cannabis, reinvest tax revenue into communities most affected by the drug war, and fund efforts to expunge prior cannabis records. It is likely that the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act would be incorporated.

Other federal legislation under review for possible submission includes the SAFE Banking Act (or Secure and Fair Enforcement Act), a bill that would allow cannabis companies to access the federally-insured banking system and capital markets without the risk of federal enforcement action, and the Strengthening the Tenth Amendment Through Entrusting States Act (or STATES Act), a bill that seeks protections for businesses and individuals in states that have legalized and comply with state laws).

Forward-Looking Statements

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-k, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please contact:

Arman Tabatabaei
IR@cannabisglobalinc.com
+1 (310)-986-4929

IR Contact:
Stuart Smith
https://www.smallcapvoice.com/
ssmith@smallcapvoice.com

SOURCE: Cannabis Global, Inc.

View source version on accesswire.com:
https://www.accesswire.com/638321/Cannabis-Global-to-Begin-Production-of-Northern-Lights-Branded-Cannabis-Products-at-Lynwood-California-Facility-April-1st

FAQ

When does Cannabis Global begin production of Northern Lights products?

Cannabis Global begins production of Northern Lights products on April 1st.

What is the significance of the Type 7 license for Cannabis Global?

The Type 7 license allows Cannabis Global to utilize various extraction methods, enhancing its product offerings.

How much of Natural Plant Extract does Cannabis Global own?

Cannabis Global owns a 56.4% controlling interest in Natural Plant Extract.

What are the tax rates at the Lynwood facility?

The Lynwood facility benefits from a 1.5% distribution tax and a 2% manufacturing tax.

What innovative technologies is Cannabis Global developing?

Cannabis Global is developing unique cannabis technologies, including secure transport and edible infusion methods.